NCT04951323 - Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

January 1, 2023

Conditions

Coronavirus Disease 2019 (Covid19)Hematopoietic Neoplasms

Interventions

DRUG

anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)

Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.

Trial Locations (1)

4000

RECRUITING

CHU Liège, Domaine du Sart-Tilman, Liège